JGC Holdings Corporation has announced that, following the successful completion of construction of the FJ3 API manufacturing facility for small and mid-size molecule drugs awarded by the Chugai Pharmaceutical Co., Ltd. subsidiary company Chugai Pharma Manufacturing Co., Ltd. (CPMC) to JGC Japan Corporation (JGC Japan), the JGC Group domestic operating company, a ceremony was held at the Fujieda Plant on January 29 of this year.

Featuring advanced production technologies that include highest-performance containment, this next-generation pharmaceutical plant reflects the pursuit of human resources efficiency and increased productivity through automation. The building is also environmentally conscious and designed for safety, including seismic isolation as an earthquake countermeasure as well as the design of facilities/structures to address potential fires or explosions.

The project was awarded by CPMC in September 2021,¹ after which JGC Japan focused closely on project management, applying the knowledge and technical expertise accumulated through numerous domestic and overseas pharmaceutical EPC projects to ensure high-quality design and construction. Construction was completed in April 2024, followed by commissioning, qualification, as well as other steps, before plant handover in November 2024. The work performed by JGC Japan was highly regarded by the client.

1: JGC Holdings press release, November 2021
JGC Awarded API Facility Construction Project for Small and Mid-Size Molecule Drugs

The completion ceremony was attended by approximately 70 people, including Chugai Pharmaceutical President and CEO Osamu Okuda, CPMC President Kenji Kamada, JGC Holdings Corporation Chairman and CEO Masayuki Sato, and JGC Japan President Yasuharu Yamaguchi.

Chugai's President and CEO Okuda expressed his gratitude to JGC Holdings and all whose work led to the successful completion and unveiling of FJ3. By the unique structure and high potency of their mid-size molecule drugs, positioned by Chugai as a key modality in their growth strategy "TOP I 2030", FJ3 stands apart from most of the world's pharmaceutical plants in its preparedness for high-volume API production, where safe, stable, mass production from the latter stages of development is indispensable. He expressed his pleasure that FJ3 completion prepares the company for the accelerated launch of new drugs.

The overall view of the completion ceremony

This project was preceded by the design and construction of an investigational synthetic drug API production facility at the CPMC Fujieda site by JGC Japan in July 2021, and JGC is currently assigned to delivering Chugai's new bio API manufacturing facility² in Utsunomiya to be completed in May 2026.

2: JGC Holdings press release, August 2023
JGC Awarded Contract for Bio API Manufacturing Facility Construction Project

The JGC Group will continue to provide optimal solutions that meet the diverse needs of clients in the pharmaceutical industry, as a leading contractor in this and other fields.

Facility exterior	Inside the facility

• NEWS inquiries - Click here

• News Releases